Roche

Roche has acquired from Simcere Zaiming the exclusive worldwide development, manufacturing and commercialization rights to SIM0660, a trispecific antibody against B‑cell–mediated diseases. Simcere Zaiming will receive up to $1.53 billion, including an upfront payment of $75 million, plus tiered double‑digit royalties on future net sales. » Más en finanzen.net

Roche has signed an exclusive license agreement for SIM0660 from Simcere and will pay an upfront $75 million; depending on development, milestone payments of up to $1.455 billion and tiered payments on future net sales are agreed. Separately, Roche is working with Treeline Biosciences on a combination study testing Treeline’s TLN‑121 together with Roche’s drugs glofitamab (Columvi) and mosunetuzumab (Lunsumio) in B‑cell lymphomas. Treeline will fund and run the phase‑1 study, with the combined use planned for Q4 2026; financial details were not disclosed. » Más en finanzen.net

Roche has signed a licensing agreement with Chinese biotech Simcere Zaiming and acquired worldwide development and commercialization rights to SIM0660, a trispecific antibody targeting B‑cell diseases. The deal includes an upfront payment of 75 million USD and could reach up to 1.53 billion USD upon achievement of milestones. The agreement reflects the trend of western pharmaceutical companies increasingly incorporating innovations from China. » Más en finanzen.net